MARKET

IONS

IONS

Ionis Pharmaceuticals
NASDAQ
83.17
+1.68
+2.06%
After Hours: 82.55 -0.62 -0.75% 19:22 01/07 EST
OPEN
82.50
PREV CLOSE
81.49
HIGH
86.15
LOW
82.40
VOLUME
3.89M
TURNOVER
--
52 WEEK HIGH
86.15
52 WEEK LOW
23.95
MARKET CAP
13.47B
P/E (TTM)
-48.5296
1D
5D
1M
3M
1Y
5Y
1D
Ionis Pharmaceuticals (IONS) Is Up 5.1% After Hepatitis B Drug Hits Phase 3 Goals - Has The Bull Case Changed?
Simply Wall St · 3h ago
BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, Boeing, Lowe's
Reuters · 9h ago
GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies
Benzinga · 11h ago
BUZZ-Ionis hits seven-year high after partner GSK reveals promising hepatitis B trial results
Reuters · 11h ago
Ionis Pharmaceuticals: Underappreciated Bepirovirsen and Multiple Late-Stage Catalysts Support Buy Rating
TipRanks · 15h ago
Ionis Advances Bepirovirsen After Positive Phase 3 Results
TipRanks · 16h ago
Ionis partner GSK reports B-Well 1, B-Well 2 studies met primary endpoint
TipRanks · 18h ago
GSK And Ionis Announce Phase 3 B Well Program Results For Bepirovirsen Supporting Functional Cure And Global Regulatory Filings Planned From Q1 2026
Benzinga · 20h ago
More
About IONS
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.

Webull offers Ionis Pharmaceuticals Inc stock information, including NASDAQ: IONS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IONS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IONS stock methods without spending real money on the virtual paper trading platform.